|
US11077101B1
(en)
|
2018-07-18 |
2021-08-03 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
US12503467B2
(en)
|
2018-12-10 |
2025-12-23 |
Ideaya Biosciences, Inc. |
2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
|
|
US12403137B2
(en)
|
2019-10-28 |
2025-09-02 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
CN116568677B
(zh)
|
2020-07-31 |
2026-07-28 |
探戈医药股份有限公司 |
可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
|
|
IL308853A
(en)
*
|
2021-06-02 |
2024-01-01 |
Ideaya Biosciences Inc |
Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
|
|
EP4458812A1
(en)
*
|
2021-12-27 |
2024-11-06 |
Medshine Discovery Inc. |
Pyrazole-1(2h)-phthalazinone compound and application thereof
|
|
EP4469447A1
(en)
*
|
2022-01-26 |
2024-12-04 |
Tango Therapeutics, Inc. |
Compounds and methods of use
|
|
CN118946549A
(zh)
*
|
2022-04-22 |
2024-11-12 |
北京望实智慧科技有限公司 |
稠和哒嗪酮化合物作为prmt5抑制剂
|
|
WO2023246873A1
(zh)
*
|
2022-06-23 |
2023-12-28 |
南京明德新药研发有限公司 |
氨基取代的杂芳基衍生物及其应用
|
|
US20250376473A1
(en)
*
|
2022-07-01 |
2025-12-11 |
Cytosinlab Therapeutics Co., Ltd. |
Prmts inhibitor and use thereof
|
|
WO2024027703A1
(zh)
*
|
2022-08-02 |
2024-02-08 |
上海艾力斯医药科技股份有限公司 |
一种prmt5抑制剂、其制备方法及应用
|
|
KR20250108633A
(ko)
*
|
2022-10-25 |
2025-07-15 |
탱고 테라퓨틱스, 인크. |
결정질 형태, 약제학적 조성물 및 이의 사용 방법
|
|
CN120265615A
(zh)
*
|
2022-11-29 |
2025-07-04 |
正大天晴药业集团股份有限公司 |
含有二氢酞嗪的化合物
|
|
WO2024118943A2
(en)
*
|
2022-11-30 |
2024-06-06 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
|
|
TW202440126A
(zh)
*
|
2022-11-30 |
2024-10-16 |
美商安進公司 |
利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
|
|
WO2024140923A1
(zh)
*
|
2022-12-30 |
2024-07-04 |
苏州浦合医药科技有限公司 |
Prmt5-mta抑制剂
|
|
CN118359607A
(zh)
*
|
2023-01-17 |
2024-07-19 |
苏州浦合医药科技有限公司 |
Prmt5-mta抑制剂
|
|
AU2024252435A1
(en)
*
|
2023-04-13 |
2025-10-16 |
Glaxosmithkline Intellectual Property (No.4) Limited |
Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor
|
|
JP2026515196A
(ja)
*
|
2023-04-28 |
2026-05-14 |
ファーマエンジン インコーポレーテッド |
Ｍｔａ協同的ｐｒｍｔ５阻害剤
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
CN116283800B
(zh)
*
|
2023-05-16 |
2023-07-18 |
英矽智能科技(上海)有限公司 |
氧代喹唑啉类化合物及其应用
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
IL326348A
(en)
*
|
2023-08-08 |
2026-04-01 |
Mirati Therapeutics Inc |
Methods and compositions for treating malignant peripheral nerve sheath tumors
|
|
IL327063A
(en)
*
|
2023-09-15 |
2026-05-01 |
Ideaya Biosciences Inc |
Methods for treating MAT2A-related diseases
|
|
CN121866246A
(zh)
*
|
2023-09-20 |
2026-04-14 |
西藏海思科制药有限公司 |
一种含氰基的杂环化合物及其用途
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN121889382A
(zh)
*
|
2023-11-08 |
2026-04-17 |
北京泰德制药股份有限公司 |
Prmt5抑制剂及其制备方法
|
|
CN122341615A
(zh)
*
|
2023-12-01 |
2026-07-03 |
上海翰森生物医药科技有限公司 |
三并环类衍生物抑制剂、其制备方法和应用
|
|
AU2025212321A1
(en)
|
2024-01-26 |
2026-08-06 |
Apeiron Therapeutics (Hong Kong) Ltd. |
Pharmaceutical composition containing prmt5 inhibitor and mat2a inhibitor
|
|
WO2025166308A1
(en)
*
|
2024-01-31 |
2025-08-07 |
Tango Therapeutics, Inc. |
Crystalline forms, pharmaceutical compositions and methods of use thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217297A1
(en)
*
|
2024-04-09 |
2025-10-16 |
Tango Therapeutics, Inc. |
Prmt5 inhibitors for use in methods of treating mta-accumulating cancer
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025250569A1
(en)
*
|
2024-05-29 |
2025-12-04 |
Amgen Inc. |
Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|